Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B

Authors:

Abstract
Background & Aims: Assessing fibrosis is essential in patients with chronic hepatitis B (CHB). The objective was to investigate the relationship between fibrosis, host and viral factors to identify non‐invasive markers of significant fibrosis in a large cohort of unselected, well‐characterized, treatment‐naïve CHB patients.Methods: Three hundred and seventy‐seven HBsAg‐positive patients (97 HBeAg‐positive and 280 HBeAg‐negative, genotypes A to E) who had liver biopsy were consecutively included. Host and viral factors (ALT, HBsAg and HBV‐DNA levels, HBV genotype and precore (PC)/basal core promoter (BCP) variants) were determined on the day of the biopsy. Fibrosis stage was assessed using METAVIR score.Results: Thirty‐nine percent of the patients had significant fibrosis (METAVIR F ≥ 2). On univariate analysis, the stages of fibrosis F ≥ 2 were associated with older age (P < 0.0001), male gender (P = 0.01), higher ALT and HBV‐DNA levels (P < 0.0001 and P = 0.0003, respectively), the presence of BCP (P < 0.0001) and BCP/PC variants (P < 0.0001). On multivariate analysis, age (P < 0.0001), the presence of HBV variants (P < 0.0001), HBV‐DNA level (P = 0.0006) and ALT level (P = 0.02) were independently associated with significant fibrosis. The diagnostic accuracy of the combination (age, ALT, HBV‐DNA, HBV variants) in predicting fibrosis F ≥ 2 was evidenced by a c‐index of 0.76 (CI 95% 0.71–0.81).Conclusions: We identified strong independent risk factors (age, ALT, HBV‐DNA, HBV variants) predicting significant fibrosis (F ≥ 2) independently of HBeAg status in patients with CHB. Patients with BCP variants have a higher risk of severe liver disease. The detection of these mutants may help to predict significant fibrosis (F ≥ 2).

This publication has 39 references indexed in Scilit: